|
1
|
Alexiou GA, Tsiouris S, Kyritsis AP,
Fotakopoulos G, Goussia A, Voulgaris S and Fotopoulos AD: The value
of 99mTc-tetrofosmin brain SPECT in predicting survival in patients
with glioblastoma multiforme. J Nucl Med. 51:1923–1926.
2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chinot OL, Wick W, Mason W, Henriksson R,
Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea
D, et al: Bevacizumab plus radiotherapy-temozolomide for newly
diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gilbert MR, Dignam JJ, Armstrong TS, Wefel
JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S,
Won M, et al: A randomized trial of bevacizumab for newly diagnosed
glioblastoma. N Engl J Med. 370:699–708. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Herrlinger U, Scha¨fer N, Steinbach J,
Weyerbrock A, Hau P, Goldbrunner R, Leutgeb B, Urbach H, Stummer W
and Glas M: The randomized, multicenter Glarius trial investigating
bevacizumab/irinotecan vs standard temozolomide in newly diagnosed,
MGMT-non-methylated glioblastoma patients: Final survival results
and quality of life. Neuro Oncol. 16:ii23–ii24. 2014.
|
|
7
|
Foster RL: Reporting guidelines: CONSORT,
PRISMA, and SQUIRE. J Spec Pediatr Nurs. 17:1–2. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Losos M, Tugwell P, Ga SW, Zello GA and Petersen JA: The
Newcastle-Ottawa scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. 2014.
|
|
9
|
Balana C, De Las Penas R, Sepúlveda JM,
Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G,
Herrero A, et al: Bevacizumab and temozolomide versus temozolomide
alone as neoadjuvant treatment in unresected glioblastoma: The
GENOM 009 randomized phase II trial. J Neurooncol. 127:569–579.
2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wirsching HG, Tabatabai G, Roelcke U,
Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao
C, Capper D, et al: Bevacizumab plus hypofractionated radiotherapy
versus radiotherapy alone in elderly patients with glioblastoma:
The randomized, open-label, phase II ARTE trial. Ann Oncol.
29:1423–1430. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Nghiemphu PL, Liu W, Lee Y, Than T, Graham
C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, et al:
Bevacizumab and chemotherapy for recurrent glioblastoma: A
single-institution experience. Neurology. 72:1217–1222.
2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lai A, Tran A, Nghiemphu PL, Pope WB,
Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, et al:
Phase II study of bevacizumab plus temozolomide during and after
radiation therapy for patients with newly diagnosed glioblastoma
multiforme. J Clin Oncol. 29:142–148. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kreisl TN, Kim L, Moore K, Duic P, Royce
C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al:
Phase II trial of single-agent bevacizumab followed by bevacizumab
plus irinotecan at tumor progression in recurrent glioblastoma. J
Clin Oncol. 27:740–745. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Schag CC, Heinrich RL and Ganz PA:
Karnofsky performance status revisited: Reliability, validity, and
guidelines. J Clin Oncol. 2:187–193. 1984.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Buie LW and Valgus J: Bevacizumab: A
treatment option for recurrent glioblastoma multiforme. Ann
Pharmacother. 42:1486–1490. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bauchet L, Mathieu-Daudé H, Fabbro-Peray
P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Lainé K,
Schlama A, et al: Oncological patterns of care and outcome for 952
patients with newly diagnosed glioblastoma in 2004. Neuro Oncol.
12:725–735. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chang SM, Parney IF, Huang W, Anderson FA
Jr, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS and Laws
ER: Patterns of care for adults with newly diagnosed malignant
glioma. JAMA. 293:557–564. 2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Graus F, Bruna J, Pardo J, Escudero D,
Vilas D, Barceló I, Brell M, Pascual C, Crespo JA, Erro E, et al:
Patterns of care and outcome for patients with glioblastoma
diagnosed during 2008-2010 in Spain. Neuro Oncol. 15:797–805.
2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chauffert B, Feuvret L, Bonnetain F,
Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro
M, Tennevet I, et al: Randomized phase II trial of irinotecan and
bevacizumab as neo-adjuvant and adjuvant to temozolomide-based
chemoradiation compared with temozolomide-chemoradiation for
unresectable glioblastoma: Final results of the TEMAVIR study from
ANOCEF†. Ann Oncol. 25:1442–1447. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Taal W, Oosterkamp HM, Walenkamp AM,
Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D,
de Vos FY, et al: Single-agent bevacizumab or lomustine versus a
combination of bevacizumab plus lomustine in patients with
recurrent glioblastoma (BELOB trial): A randomised controlled phase
2 trial. Lancet Oncol. 15:943–953. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Prados M, Cloughesy T, Samant M, Fang L,
Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, et
al: Response as a predictor of survival in patients with recurrent
glioblastoma treated with bevacizumab. Neuro Oncol. 13:143–151.
2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pérez-Larraya J, Lahutte M, Petrirena G,
Reyes-Botero G, González-Aguilar A, Houillier C, Guillevin R,
Sanson M, Hoang-Xuan K and Delattre JY: Response assessment in
recurrent glioblastoma treated with irinotecan-bevacizumab:
Comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F
criteria. Neuro Oncol. 14:667–673. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kazazi-Hyseni F, Beijnen JH and Schellens
JH: Bevacizumab. Oncologist. 15:819–825. 2010.PubMed/NCBI View Article : Google Scholar
|
